Close X
Attorney Spotlight

How does Jordana Nelson's prior experience as a general counsel inform her work with firm clients? Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

The M&A Advisor Winner 2017The M&A Advisor announced the winners of the 16th Annual M&A Advisor Awards on Monday, November 13 at the 2017 M&A Advisor Awards. Bass, Berry & Sims was named a winner in the two categories related to the following deals:

M&A Deal of the Year (from $1B-$5B) – Acquisition of CLARCOR Inc. by Parker Hannifin Corporation

Corporate/Strategic Deal of the Year (over $1B) – Acquisition of BNC Bancorp by Pinnacle Financial Partners

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices

Events

May 8, 2012

Bass, Berry & Sims healthcare attorneys John Kelly and Danielle Sloane will present the topic "Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices," at an upcoming Nashville Council of Health Care Attorneys (NCHCA) meeting. This presentation will include:

  • Overview of what constitutes off label use versus off label promotion and why physicians prescribe off-label;
  • Government recent enforcement of off-label promotion violations;
  • The pharmaceutical and device companies attempting to limit the FDA's reach with the first amendment;
  • FDA response to industry requests for additional clarity on when it is permissible for pharmaceutical and device companies to distribute information regarding off-label uses; and
  • An ethical debate and evaluation of competing interests: regulatory oversight versus off-label promotion and use.

This course has been approved for one hour of dual CLE credit.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.